Methylphenidate Stada

Methylphenidate, the active ingredient in Methylphenidate Stada, is a central nervous system stimulant presented as a tablet for oral use. It is indicated for the management of attention deficit hyperactivity disorder and narcolepsy, helping improve focus, attention and wakefulness in children, adolescents and adults. The medication works by increasing the levels of dopamine and norepinephrine in the brain, which contributes to its therapeutic effect.

GNH USA supplies Methylphenidate Stada as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide.

Methylphenidate Stada is a central nervous system stimulant used in disorders characterized by attention deficits and excessive daytime sleepiness. - Attention deficit hyperactivity disorder (children and adolescents): improves concentration, reduces hyperactivity and supports academic performance. - Attention deficit hyperactivity disorder (adults): enhances focus, reduces impulsivity and aids occupational functioning. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

Methylphenidate Stada may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Insomnia: difficulty initiating or maintaining sleep, leading to daytime fatigue. - Loss of appetite: reduced hunger which may result in weight loss over time. - Headache: mild to moderate cranial pain that can be intermittent. - Stomach pain: abdominal discomfort, nausea or dyspepsia.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, tachycardia or arrhythmia requiring medical attention. - Psychiatric symptoms: emergence or worsening of anxiety, agitation, mood swings or psychotic features. - Growth suppression: noticeable reduction in height velocity in pediatric patients during prolonged therapy.

When prescribing Methylphenidate Stada, clinicians should consider several precautions to ensure safe use. - Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Psychiatric history: screen for pre‑existing anxiety, bipolar disorder or psychosis. - Substance abuse: avoid use in patients with a history of drug dependence. - Growth monitoring: regularly assess height and weight in children during treatment. - Drug interactions: review concomitant medications that affect catecholamine pathways. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Methylphenidate Stada can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis or serotonin syndrome. - Tricyclic antidepressants: increased risk of cardiovascular side effects and heightened stimulant effect.

Moderate Interactions (Monitor Closely): - Antihypertensives: methylphenidate may reduce their effectiveness, requiring blood pressure monitoring. - Proton pump inhibitors: may slightly increase methylphenidate plasma levels. - Anticonvulsants (e.g., carbamazepine): may decrease methylphenidate concentrations, reducing therapeutic effect.